ArticleGut2026
Rate and clinical predictors of skeletal muscle loss in patients with cirrhosis.
Article in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSkeletal muscle mass predicts outcomes in cirrhosis and represents a therapeutic target. However, the natural rate of muscle change in this population remains poorly defined.
objectiveWe characterised longitudinal skeletal muscle change and its association with clinical outcomes in cirrhosis.
designThis cohort study enrolled ambulatory adults with cirrhosis awaiting liver transplantation at a tertiary centre who underwent at least two abdominal CT scans between February 2015 and January 2021. Skeletal muscle index (SMI) at L3 was quantified and normalised for height. Annualised percent change in SMI (ΔSMI/year%) was calculated. The primary outcome was waitlist mortality, defined as death or delisting for being too ill for transplantation.
resultsAmong 364 patients (median age 62 years; 68% male; model for end-stage liver disease-sodium (MELD-Na) 12), the median (IQR) ΔSMI/year% was -1.6% (-7.4 to +3.7). Rapid muscle loss (RML) was defined as the worst quartile of ΔSMI/year% (< -7.4%; n=91). Independent predictors of RML included ascites (OR 1.77, 95% CI 1.00 to 3.12) and higher MELD-Na (OR 1.06, 95% CI 1.00 to 1.13). Cumulative waitlist mortality was significantly higher in patients with RML than in those without RML at 12 months (32% vs 10%) and 24 months (75% vs 27%) (log-rank p<0.001). RML independently predicted waitlist mortality in adjusted Cox models (HR 3.43-3.52).
conclusionPatients with cirrhosis had a median skeletal muscle loss of 1.6%/year. In this cohort, RML independently predicted waitlist mortality and was associated with ascites and MELD-Na. These data could inform effect-size estimates for future trials targeting sarcopenia in cirrhosis with low-to-moderate MELD-Na.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.